Trial Profile
Prospective Evaluation of Dual Antiplatelet Therapy Compliance and Outcomes After Treatment With the Xience Stent.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Antiplatelets; Aspirin; Clopidogrel
- Indications Coronary artery disease; Stent thrombosis
- Focus Adverse reactions
- Acronyms PREDICT-X
- 06 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 03 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 11 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.